---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-006976"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2024-01-26T23:59:59+00:00"
generated_at: "2026-06-06T16:39:10.145705+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics enters $1.0M at-the-market equity distribution agreement with H.C. Wainwright

## Summary
- Enters ATM agreement to sell up to $1.0M of common stock through H.C. Wainwright as agent.
- Commission of 3.0% of gross proceeds; net proceeds for general corporate purposes including trials.
- Company not obligated to sell any shares; offering made under Form S-3 filed Jan 26, 2024.
- At-the-market offering allows stock sales at prevailing market prices over time.

## SEC filing metadata
- accession: 0001104659-24-006976
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2024-01-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465924006976/0001104659-24-006976-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465924006976/tm244107d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-006976
- JSON: https://secwatch.observer/filing/0001104659-24-006976.json
- Plain text: https://secwatch.observer/filing/0001104659-24-006976.txt

## Key facts
- Material Agreements
  Aprea Therapeutics, Inc. entered into Sales Agreement with H.C. Wainwright & Co., LLC valued at up to $1.0 million (effective 2024-01-26).
  - Action: entry
  - Agreement: atm program
  - Counterparty: H.C. Wainwright & Co., LLC
  - Value: up to $1.0 million
  - Effective: 2024-01-26
  source text: On January 26, 2024, Aprea Therapeutics, Inc. (the “Company”) entered into an at the market offering agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “HCW”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465924006976/0001104659-24-006976-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.